Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus chemotherapy in squamous NSCLC
NCT01285609Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2011
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 36
01
Overview
A Phase 3 trial of ipilimumab in non-small cell lung cancer, squamous cell carcinoma (NSCLC), sponsored by Bristol Myers Squibb. Started Jan 2011; status: completed.
02
Drugs
ipilimumab
03
Conditions
non-small cell lung cancer, squamous cell carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT01285609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01285609.